257 Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage ovarian cancer in Australia, South Korea and Taiwan. (4th December 2020)

• Record Type: Journal Article
• Authors: Chou, Hung-Hsueh; Defazio, Anna; Kim, Byoung-Gie; Chang, Chih-Long; Bowtell, David; Hsu, Heng-Cheng; Traficante, Nadia; Jeong, Soo Young; Cheng, Wen-Fang; Fereday, Sian
• Is Part Of: International journal of gynecological cancer. Volume 30(2020)Supplement 4
• Page Start: A59
• Page End: A60
• Publication Date: 2020-12-04
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2020-ESGO.108
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: Epithelial ovarian cancer (EOC) is often associated with diagnosis at an advanced stage, poor prognosis and high mortality. Limited data exist on the clinical management of ovarian cancer (OC) patients in the Asia-Pacific region. We evaluated secondary databases from Australia, South Korea and Taiwan to review the current standard of care in a real world setting prior to the introduction of poly-(adenosine diphosphate-ribose) polymerase inhibitor (PARPi) maintenance after first-line chemotherapy. Methodology: Data from medical records of nearly 1, 000 women diagnosed with advanced-stage EOC in a 5 year period, between January 2014 and December 2018 were obtained from clinic- (Taiwan, South Korea) and cohort-based (Australia) OC registries. Patients on first-line maintenance with PARPis were excluded. Treatment characteristics including the use of neoadjuvant therapy, outcomes of cytoreductive surgery and the use of bevacizumab as maintenance were summarised with descriptive statistics. Duration of treatment, time to real world progression and any other time-to-event outcomes (e.g. overall survival, platinum based chemotherapy-free interval and time to first subsequent treatment and surgery) will be analysed using Kaplan Meier methodology. Results: Table 1 describes the demographic characteristics and treatment patterns of the study population. Overall, patients received a median of 6 cycles of primary platinum chemotherapy; complete or partial remission was the most common outcome. For patients with data on progression, the median time to first progression in months (two sided 95% confidence interval) was 16.2 (14.6–18.1), 17.9 (16.2–19.3) and 17.2 (14.7 19.7) in Australian, South Korean and Taiwanese patients, respectively. From the currently available dataset of patients with high grade serous type investigated for germline BRCA1/2 mutations: 30/169, 17.8% (Australia), 80/354, 22.6% (South Korea) and 7/21, 33.3% (Taiwan) of patients tested positive for germline BRCA1/2 mutations. Conclusion: Although there were differences in demographics and treatment patterns, advanced-stage EOC had poor prognosis and relatively short progression-free intervals across Asia-Pacific countries with well developed healthcare systems, highlighting the need to develop novel approaches to improve patient outcomes. Variation in the germline BRCA1/2 mutation rates across three datasets is probably due to differences in the composition of the contributing registries (clinic or cohort-based). Disclosures: Anna DeFazio has received a research grant from AstraZeneca. David Bowtell has received research grants from AstraZeneca, BeiGene and Genentech Roche. David Bowtell is also a consultant for Exo Therapeutics. Sian Fereday has received a research grant from AstraZeneca. Nadia Traficante has received a research grant from AstraZeneca Byoung-Gie Kim has received a research grant from AstraZeneca, Cellid and Eutilex. Soo Young Jeong, Hung-Hsueh Chou, Chih-Long Chang, Heng-Chen Hsu and Wen-Fang Cheng have no conflict of interests to be declared